AU4552200A - Method of treating psychotic disorders - Google Patents

Method of treating psychotic disorders

Info

Publication number
AU4552200A
AU4552200A AU45522/00A AU4552200A AU4552200A AU 4552200 A AU4552200 A AU 4552200A AU 45522/00 A AU45522/00 A AU 45522/00A AU 4552200 A AU4552200 A AU 4552200A AU 4552200 A AU4552200 A AU 4552200A
Authority
AU
Australia
Prior art keywords
psychotic disorders
treating psychotic
treating
disorders
psychotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45522/00A
Other languages
English (en)
Inventor
Cornelis G. Kruse
Stephen K. Long
Johannes A. M. Van Der Heijden
Roelof Van Hes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Publication of AU4552200A publication Critical patent/AU4552200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
AU45522/00A 1999-05-12 2000-04-14 Method of treating psychotic disorders Abandoned AU4552200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99201524 1999-05-12
EP99201524 1999-05-12
PCT/EP2000/003506 WO2000069424A2 (fr) 1999-05-12 2000-04-14 Methode de traitement de troubles psychotiques

Publications (1)

Publication Number Publication Date
AU4552200A true AU4552200A (en) 2000-12-05

Family

ID=8240207

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45522/00A Abandoned AU4552200A (en) 1999-05-12 2000-04-14 Method of treating psychotic disorders

Country Status (5)

Country Link
EP (1) EP1200072A2 (fr)
JP (1) JP2002544223A (fr)
AU (1) AU4552200A (fr)
CA (1) CA2373855A1 (fr)
WO (1) WO2000069424A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028685A1 (es) * 2000-06-14 2003-05-21 Lundbeck & Co As H Derivados de indol
DE102004023632A1 (de) * 2004-05-10 2005-12-08 Grünenthal GmbH Substituierte Cyclohexylcarbonsäure-Derivate
DE102004023635A1 (de) * 2004-05-10 2006-04-13 Grünenthal GmbH Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate
DE102004023522A1 (de) * 2004-05-10 2005-12-01 Grünenthal GmbH Substituierte Cyclohexyl-1,4-diamin-Derivate
DE102004023508A1 (de) * 2004-05-10 2005-12-08 Grünenthal GmbH Säurederivate substituierter Cyclohexyl-1,4-diamine
DE102004023501A1 (de) * 2004-05-10 2005-12-01 Grünenthal GmbH Oxosubstituierte Cyclohexyl-1,4-diamin-Derivate
DE102004023506A1 (de) * 2004-05-10 2005-12-01 Grünenthal GmbH Kettenverlängerte substituierte Cyclohexyl-1,4-diamin-Derivate
DE102004023507A1 (de) * 2004-05-10 2005-12-01 Grünenthal GmbH Substituierte Cyclohexylessigsäure-Derivate
JP2008521771A (ja) * 2004-11-26 2008-06-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 改良された抗精神病活性および抗不安症活性を有するイソキサゾリン−インドール誘導体
KR20070091009A (ko) * 2004-12-07 2007-09-06 솔베이 파마슈티칼스 비. 브이 도파민-ｄ2 수용체 및 세로토닌 재흡수 부위에 대한친화성이 조합된 테트라하이드로피리딘-4-일 인돌
US7371769B2 (en) 2004-12-07 2008-05-13 Solvay Pharmaceuticals B.V. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
US8101619B2 (en) 2004-12-08 2012-01-24 Solvay Pharmaceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124332A (en) * 1991-01-28 1992-06-23 Warner-Lambert Company Substituted indoles as central nervous system agents
CA2091204C (fr) * 1992-03-11 1997-04-08 Ronald J. Mattson Piperazinyl- et piperidinylcyclohexanes contre l'ischemie
DE4414113A1 (de) * 1994-04-22 1995-10-26 Merck Patent Gmbh 3-Indolylpiperidine
DE19500689A1 (de) * 1995-01-12 1996-07-18 Merck Patent Gmbh Indolpiperidin-Derivate
AR004229A1 (es) * 1995-11-06 1998-11-04 Wyeth Corp Derivados indolalquilo de benzodioxanmetilamina y su uso para preparar medicamentos
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
ZA9711376B (en) * 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
AR020773A1 (es) * 1998-10-16 2002-05-29 Duphar Int Res Compuesto derivados de 3-(tetrahidropiridin-4-il)indol, metodo para prepararlo, una composicion farmaceutica que los contiene, metodo para preparar dicha composicion y uso del compuesto

Also Published As

Publication number Publication date
WO2000069424A3 (fr) 2001-06-07
JP2002544223A (ja) 2002-12-24
CA2373855A1 (fr) 2000-11-23
WO2000069424A2 (fr) 2000-11-23
EP1200072A2 (fr) 2002-05-02

Similar Documents

Publication Publication Date Title
AU1294401A (en) Methods for treating fibroproliferative diseases
HU0001471D0 (en) New method of treatment
AU3977700A (en) Method of treating neurological disorders
AU2001286983A1 (en) Method of treatment
AU5042000A (en) Methods of treating proliferative disorders
AU4552200A (en) Method of treating psychotic disorders
AU2002229452A1 (en) Method of treating neurological disorders using acetone derivatives
AU2001232263A1 (en) Method of treating seeds
AU2964500A (en) Method of micro-fabrication
AU3757300A (en) Method of treating anxiety disorders
AU2001288792A1 (en) Method of treating neurologic disorders
AU1133901A (en) Method of treating metabolic disorders
AU2080201A (en) Treatment of addiction disorders
AU2001262177A1 (en) Method of treatment
AUPP508798A0 (en) Method of treating psoriasis
AU1282099A (en) Method for treatment of disorders of attention
AU3753500A (en) Methods of treating fibrinogen-related disorders
AU4598400A (en) Method of treatment
AU4985200A (en) Methods of treating hypertension
AU2382601A (en) Novel method of treatment
AU1108101A (en) Method of treating plants
AU1784701A (en) Method of treating neuroblastoma
AU8031700A (en) Method of treating fibrosis
AU8038400A (en) Method of treatment of influenza
AU2001236909A1 (en) Method of treating disorders of the eye

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase